Skip to main content
Evidence Snapshot

Mitogen-activated protein kinase 14

CHEMBL260 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:01:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL260
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitogen-activated protein kinase 14 as ChEMBL target CHEMBL260, mapped to UniProt Q16539. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitogen-activated protein kinase 14
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL260
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q16539
Mitogen-activated protein kinase 14
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mitogen-activated protein kinase 14 matters

As of 2026-09-13

Mitogen-activated protein kinase 14 is reviewed as Mitogen-activated protein kinase 14 (UniProt Q16539); Mitogen-activated protein kinase 14 shows late clinical disease relevance led by acute coronary syndrome. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 34 approved drugs, 9114 compounds, and 1550 assays, with lead potency reaching pChEMBL 10.5.

Disease context
acute coronary syndrome

Mitogen-activated protein kinase 14 shows late clinical disease relevance led by acute coronary syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include LOSMAPIMOD.

Start review with acute coronary syndrome because it currently carries late clinical support. Linked drugs include LOSMAPIMOD. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 34 approved drugs, 9114 compounds, and 1550 assays for this target. The dominant activity type is IC50. CHEMBL5186216 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL5186216 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
34 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mitogen-activated protein kinase 14 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16539, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acute coronary syndrome is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9114
Total Compounds
1550
Total Assays
34
Approved Drugs
IC50: 8121.0, KI: 1622.0, EC50: 25.0, KD: 575.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5186216
 10.5 IC50 —
No preferred name
CHEMBL3640006
 10.4 IC50 —
No preferred name
CHEMBL103667
 10.3 Kd Clinical
No preferred name
CHEMBL1088796
 10.3 Kd —
No preferred name
CHEMBL5174953
 10.3 IC50 —

Approved Drugs

Structure Compound First Approval
TOVORAFENIB
CHEMBL3348923
 2024
LENVATINIB
CHEMBL1289601
 2015
PONATINIB
CHEMBL1171837
 2012
REGORAFENIB
CHEMBL1946170
 2012
NILOTINIB
CHEMBL255863
 2007
DASATINIB ANHYDROUS
CHEMBL1421
 2006
DASATINIB
CHEMBL5416410
 2006
SORAFENIB
CHEMBL1336
 2005
GEFITINIB
CHEMBL939
 2003
ETORICOXIB
CHEMBL416146
 2002
CELECOXIB
CHEMBL118
 1998
MONTELUKAST
CHEMBL787
 1998
ZAFIRLUKAST
CHEMBL603
 1996
TANNIC ACID
CHEMBL506247
 1982
HEXACHLOROPHENE
CHEMBL496
 1949
BITHIONOL
CHEMBL290106
 —
TRIBROMSALAN
CHEMBL24944
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T05:01:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL260